Sirolimus
Drug Category | Drug | IHD Dosing | Administration Timing Around HD Session |
---|---|---|---|
Immunosuppressants | Sirolimus | Normal dose based on indication | Administer Anytime During HD |
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
---|---|---|---|---|---|---|---|
914 | N/A | 57-63 | N/A | 92 | 12 | N/A | 0 (N/A) |
References:
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB00877
- Ferron G, Mishina E, Zimmerman J, Jusko W. Population pharmacokinetics of sirolimus in kidney transplant patients. Clinical pharmacology and therapeutics 1997; 61(4), 416-28.